Showing results (111-120 of 129) with videos related to

Sort By:
Pageof 13
Arthritis and Rheumatism|May 12, 2012
Periodontal disease and the oral microbiota in new-onset rheumatoid arthritisJose U Scher, Carles Ubeda, Michele Equinda, et al.
British Journal of Pharmacology|June 20, 2006
Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosisEdwin S L Chan, Maria Carmen Montesinos, Patricia Fernandez, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 21, 2024
Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout TrialLindsay N Helget, Anne Davis-Karim, James R O'Dell, et al.
Journal of Clinical and Translational Science|August 13, 2019
Come from away: Best practices in mini-sabbaticals for the development of young investigators: a White Paper by the SEQUIN (mini-Sabbatical Evaluation and QUality ImprovemeNt) GroupMichael H Pillinger, Stephenie C Lemon, Martin S Zand, et al.
The Journal of Biological Chemistry|May 4, 2007
Helicobacter pylori stimulates gastric epithelial cell MMP-1 secretion via CagA-dependent and -independent ERK activationMichael H Pillinger, Nada Marjanovic, Seok-Yong Kim, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 26, 2026
Efficacy and Safety of Nanoencapsulated Sirolimus plus Pegadricase: Results from the Randomized, Placebo-Controlled Phase 3 TrialsHerbert S B Baraf, Puja P Khanna, Milan Petronijevic, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 16, 2023
Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in GoutLindsay N Helget, James R O'Dell, Jeff A Newcomb, et al.
Rheumatology (Oxford, England)|December 14, 2025
Systemic inflammation in gout and the impact of treat-to-target urate-lowering therapyAustin M Wheeler, Tanner J Ourada, Spencer Q Jones, et al.
Seminars in Arthritis and Rheumatism|August 9, 2025
Real-world persistence of urate-lowering therapy following a treat-to-target intervention: A two-year follow-up analysis of the STOP gout trialSamantha Kohn, Harlan Sayles, Lindsay N Helget, et al.
Pageof 13